This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gibril, F. Articles by Jensen, R. T. Search for Related Content PubMed PubMed Citation Articles by Gibril, F. Articles by Jensen, R. T.

Prospective Study of the Natural History of Gastrinoma in Patients with MEN1: Definition of an Aggressive and a Nonaggressive Form

Digestive Diseases Branch, National Institute of Diabetes and Digestive, and Kidney Diseases, National Institutes of Health (F.G., J.V.O., S.B., R.T.J.), Bethesda, Maryland 20892-1804; and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health (D.J.V.), Bethesda, Maryland 20892-8325

Address all correspondence and requests for reprints to: Dr. Robert T. Jensen, Digestive Diseases Branch, National Institute of Diabetes and Digestive, and Kidney Diseases, National Institutes of Health, Building 10, Room 9C-103, 10 Center Drive, MSC 1804, Bethesda, Maryland 20892-1804.

Abstract

The natural history of pancreatic endocrine tumors (PETs) in patients with MEN1 is largely unknown. Recent studies in patients with sporadic PETs show that in a subset, tumor growth is aggressive. To determine whether PETs in patients with MEN1 show similar growth behavior, we report results from a long-term prospective study of 57 patients with MEN1 and Zollinger-Ellison syndrome. All patients had tumor imaging studies yearly, and the mean follow-up was 8 yr. Only patients with PETs 2.5 cm or larger underwent abdominal surgical exploration. Hepatic metastases occurred in 23%, and in 14% tumors demonstrated aggressive growth. Three tumor-related deaths occurred, each due to liver metastases, and in each, aggressive tumor growth was present. Overall, 4% of the study group, 23% with liver metastases and 38% with aggressive disease, died. Aggressive growth was associated with higher gastrins and larger tumors. Patients with liver metastases with aggressive growth differed from those with liver metastases without aggressive growth in age at MEN1 onset or diagnosis and primary tumor size. Survival was decreased (P = 0.0012) in patients with aggressive tumor growth compared with those with liver metastases without aggressive growth or with no liver metastases without aggressive growth. Based on these results a number of factors were identified that may be clinically useful in determining in which patients aggressive tumor growth may occur. These results demonstrate in a significant subset of patients with MEN1 and Zollinger-Ellison syndrome, aggressive tumor growth occurs and can lead to decreased survival. The identification of prognostic factors that identify this group will be important clinically in allowing more aggressive treatment options to be instituted earlier.

This article has been cited by other articles:

				M. J. Berna, B. Annibale, M. Marignani, T. V. Luong, V. Corleto, A. Pace, T. Ito, D. Liewehr, D. J. Venzon, G. Delle Fave, et al. A Prospective Study of Gastric Carcinoids and Enterochromaffin-Like Cell Changes in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Identification of Risk Factors J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1582 - 1591. [Abstract] [Full Text] [PDF]

				K. M. Hoffmann, F. Gibril, L. K. Entsuah, J. Serrano, and R. T. Jensen Patients with Multiple Endocrine Neoplasia Type 1 with Gastrinomas Have an Increased Risk of Severe Esophageal Disease Including Stricture and the Premalignant Condition, Barrett's Esophagus J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 204 - 212. [Abstract] [Full Text] [PDF]

				M Gugger, B Waser, A Kappeler, A Schonbrunn, and J C Reubi Cellular detection of sst2A receptors in human gastrointestinal tissue Gut, October 1, 2004; 53(10): 1431 - 1436. [Abstract] [Full Text] [PDF]

				M Gugger, B Waser, A Kappeler, A Schonbrunn, and J. Reubi Immunohistochemical Localization of Somatostatin Receptor sst2A in Human Gut and Lung Tissue: Possible Implications for Physiology and Carcinogenesis Ann. N.Y. Acad. Sci., April 1, 2004; 1014(1): 132 - 136. [Abstract] [Full Text] [PDF]

				B. Asgharian, Y.-J. Chen, N. J. Patronas, P. L. Peghini, J. C. Reynolds, A. Vortmeyer, Z. Zhuang, D. J. Venzon, F. Gibril, and R. T. Jensen Meningiomas May Be a Component Tumor of Multiple Endocrine Neoplasia Type 1 Clin. Cancer Res., February 1, 2004; 10(3): 869 - 880. [Abstract] [Full Text] [PDF]

				F. Gibril, Y.-J. Chen, D. S. Schrump, A. Vortmeyer, Z. Zhuang, I. A. Lubensky, J. C. Reynolds, A. Louie, L. K. Entsuah, K. Huang, et al. Prospective Study of Thymic Carcinoids in Patients with Multiple Endocrine Neoplasia Type 1 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1066 - 1081. [Abstract] [Full Text] [PDF]

				S. U. Goebel, M. Iwamoto, M. Raffeld, F. Gibril, W. Hou, J. Serrano, and R. T. Jensen HER-2/neu Expression and Gene Amplification in Gastrinomas: Correlations with Tumor Biology, Growth, and Aggressiveness Cancer Res., July 1, 2002; 62(13): 3702 - 3710. [Abstract] [Full Text] [PDF]

				S. J. Marx and L. K. Nieman Aggressive Pituitary Tumors in MEN1: Do They Refute the Two-Hit Model of Tumorigenesis? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 453 - 456. [Full Text] [PDF]